A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager.” This type of immunotherapy ignites our own immune arsenal to fight cancer.
Continue Reading
News Source: medicalxpress.com
Leave a Reply